Editors
Michele Ghielmini
Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
Silvia Montoto
Department of Haemato-Oncology, St Bartholomew’s Hospital, London, UK
Contributors
Chapter 1: The Immune System
Davies A. Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK
Chapter 2: Diagnosing Lymphomas
Soldini D. Istituto Cantonale di Patologia, Locarno, Switzerland
Mazzucchelli L. Istituto Cantonale di Patologia, Locarno, Switzerland
Chapter 3: The WHO Lymphoma Classification
Carvajal-Cuenca A. Department of Pathology, Hospital Mexico, University of Costa Rica, San José, Costa Rica
Campo E. Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, Spain
Chapter 4: Staging and Response Assessment in Lymphoma Patients
Borra A. Haematology Department and BMT Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
Gallamini A. Research, Innovation and Statistics Department, A Lacassagne Cancer Center, Nice, France
Chapter 5: Common Treatments for Lymphoma
Rodriguez-Abreu D. Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
Provencio M. Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Chapter 6: Diffuse Large B-Cell Lymphoma
Chiappella A. Hematology 2, Città della Salute e della Scienza, San Giovanni Battista Hospital and University, Torino, Italy
Vitolo U. Hematology, Città della Salute e della Scienza, Hospital and University, Torino, Italy
Chapter 7: Follicular Lymphoma
Moccia A.A. Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
Ghielmini M. Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
Chapter 8: Chronic Lymphocytic Leukaemia / Small Lymphocytic Lymphoma
Norin S. Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Kimby E. Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Chapter 9: Mantle Cell Lymphoma
Weiglein T. Department of Medicine III, Klinikum der Universität München, München, Germany
Dreyling M. Department of Medicine III, Klinikum der Universität München, München, Germany
Chapter 10: Extranodal marginal Zone Lymphoma of MALT Type
Bertoni F. Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Zucca E. Division of Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Chapter 11: Peripheral T-Cell Lymphomas
Pedersen M.B. Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
d’Amore F. Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
Chapter 12: Hodgkin Lymphoma
Eichenauer D.A. First Department of Internal Medicine, University Hospital Cologne; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany
Engert A. First Department of Internal Medicine, University Hospital Cologne; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany
Chapter 13: Aetiology and Epidemiology
Costas L. Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona; CIBER Epidemiologia y Salud Publica, Madrid, Spain
de Sanjose S. Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona; CIBER Epidemiologia y Salud Pública, Madrid, Spain
Chapter 14: History of Lymphoma Classification
Ponzoni M. Vita-Salute San Raffaele University, Haematopathology Diagnostic Area - Pathology Unit, Lymphoma, Leukemia and Myeloma Units, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy
Ferreri A.J.M. Unit of Lymphoid Malignancies, Division of Onco-Hematological Medicine, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy
Chapter 15: Molecular Biology of Lymphomas
Bertoni F. Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Chapter 16: New Drugs and Novel Treatment Strategies
Hess G. Department of Internal Medicine, Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-Universität, Mainz, Germany
Chapter 17: Cutaneous Lymphoma
Willemze R. Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
Chapter 18: Peripheral T-Cell Lymphomas (Extranodal)
Ballova V. National Cancer Institute (Narodny Onkologicky Ustav), Bratislava, Slovakia
Chapter 19: Non-MALT Marginal Zone Lymphomas
Montalban C. Department of Hematology, MD Anderson Cancer Center, Madrid, Spain
Chapter 20: Lymphoplasmacytic Lymphoma / Waldenström’s Macroglobulinemia
Kastritis E. Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
Dimopoulos M.A. Department of Clinical Therapeutics, National and Kapodistrian, University of Athens School of Medicine, Athens, Greece
Chapter 21: Burkitt Lymphoma and Lymphoblastic Lymphoma
Fridrik M.A. Department of Internal Medicine 3, Center for Hematology and Medical Oncology, Medical Faculty Johannes Kepler University, Linz, Austria
Chapter 22: Extranodal Lymphomas
Ferreri A.J.M. Unit of Lymphoid Malignancies, Division of Onco-Hematological Medicine, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy
Ponzoni M. Vita-Salute San Raffaele University, Haematopathology Diagnostic Area - Pathology Unit, Lymphoma, Leukemia and Myeloma Units, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy
Chapter 23: Lymphomas in the Immunocompromised Patient
Montoto S. Department of Haemato-oncology, St Bartholomew’s Hospital, London, UK
Declarations of Interest
V Ballova: No conflicts of interest.
F Bertoni: Received funds for research projects or advisory board participation from: Bayer, CTI Life Sciences, Celgene, EMD Serono Research, Italfarmaco, Oncoethix, Piqur, Sigma Tau.
A Borra: No conflicts of interest.
E Campo: No conflicts of interest.
A Carvajal-Cuenca: No conflicts of interest.
A Chiappella: No conflicts of interest.
L Costas: No conflicts of interest.
F d’Amore: Research funding: Sanofi, Amgen; Advisory board/speaker honoraria: Takeda/Millennium, CTI, Roche, Bayer, Kyowa-Kirin.
A Davies: No conflicts of interest.
MA Dimopoulos: Honoraria from Celgene, Janssen, Onyx.
M Dreyling: No conflicts of interest.
DA Eichenauer: No conflicts of interest.
A Engert: Research funding/consultancy: Millennium/Takeda, Affimed.
AJM Ferreri: No conflicts of interest.
MA Fridrik: Consultant or advisory role: Roche Austria; Honoraria: Roche Austria; Other remuneration: Roche Austria.
A Gallamini: No conflicts of interest.
M Ghielmini: Honoraria: Roche, Millennium, Mundipharma, Celgene, Janssen, Gilead.
G Hess: Research funding: Roche, Mundipharma, Pfizer, CTI, Celgene; Advisory board /Speaker honoraria: Roche, Janssen, Celgene, Pfizer, CTI, Novartis.
E Kastritis: No conflicts of interest.
E Kimby: Conducting research in part sponsored by Roche and Pfizer; Advisory boards: Janssen, Gilead, Pharmacyclics; Educational talks in meetings sponsored with unrestricted grants from Roche and Celgene.
L Mazzucchelli: No conflicts of interest.
AA Moccia: No conflicts of interest.
C Montalban: No conflicts of interest.
S Montoto: Honoraria: Roche.
S Norin: Grant and lecture honoraria: Roche; Lecture honoraria: Mundipharma; National principal nvestigator in a company-sponsored study: Janssen-Cilag: Local principal investigator in company-sponsored studies: GlaxoSmithKline.
MB Pedersen: No conflicts of interest.
M Ponzoni: No conflicts of interest.
M Provencio: No conflicts of interest.
D Rodriguez-Abreu: No conflicts of interest.
S de Sanjose: No conflicts of interest.
D Soldini: No conflicts of interest.
U Vitolo: Advisory board/speakers’ bureau: Roche, Celgene, Janssen, Mundipharma.
T Weiglein: No conflicts of interest.
R Willemze: Advisory board/speakers’ bureau: Takeda, Actelion, Excerpta Medica.
E Zucca: Funds for research projects or advisory board participation from: Celgene, GlaxoSmithKline, Mundipharma, Oncoethix, Novartis, Roche.
